Physician profile
Sofya Tokman
NPI 1396070983
$4,567.76
in general payments reported to CMS, 2019-2025
18 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.24 · 2020: $22.21 · 2021: $187 · 2022: $51.00 · 2023: $2,123 · 2024: $1,572 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,660 · Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,660.00 |
| Food and Beverage | $1,596.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,860.00 | 2023 | Cellex |
| Paragonix Technologies, INC. | $864.98 | 2024-2025 | Baroguard, Lungguard, Sherpapak |
| Pfizer INC. | $800.00 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $297.80 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $179.47 | 2023 | Mitraclip |
| Astellas Pharma US INC | $164.98 | 2021 | |
| Insmed, INC. | $70.96 | 2025 | Arikayce |
| United Therapeutics Corporation | $68.87 | 2019-2024 | Tyvaso |
| Medtronic, INC. | $62.48 | 2023 | Gi Genius |
| Eurofins Viracor, LLC | $32.20 | 2019 | |
| Viatris Specialty LLC | $23.83 | 2025 | Yupelri |
| Atricure, INC. | $23.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.21 | 2020 | |
| Gilead Sciences, INC. | $20.99 | 2023 | |
| Verona Pharma, INC. | $20.83 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.66 | 2025 | Glassia |
| Genentech USA, INC. | $19.97 | 2025 | Xolair |
| Genzyme Corporation | $13.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofya Tokman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.